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Conclusions:  Low dose radiotherapy provides effect palliation 
of distressing symptoms resulting from cutaneous KS with 
acceptable toxicity. 
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A PRACTICAL ENERGY MODULATION TECHNIQUE TO AVOID 
ENUCLEATION FOR ADVANCED PERIOCULAR CANCERS 
Jon-Paul Voroney, Alana Hudson, Yannick Poirier, David Spencer, 
Ferenc Jacso, Kevin Martell 
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Purpose: Consider a 2x2x1.5 cm basal cell cancer invading right 
medial canthus periocular embryonic fusion plane. Usual 
techniques fail: an irregular PTV 4x4x2.5 cm deep, a concave 
surface, a deep tumour, and adjacent ocular structures. 
Oculoplastics/Mohs risk enucleation. Electrons with an internal 
eye shield require bolus and limit energy to 9 MeV. High energy 
conformal RT risks medial retinal damage. Systemic agents may 
palliate but do not cure. We describe low energy electron RT (e-
) with an orthovoltage (ortho) bump. “Bump” modulates energy 
by replacing some e-dose with ortho to increase surface dose and 
optimize dose distribution. Bump applies to any anatomic 
location to a depth of 2-3 cm. Bump can use e- with a tungsten 
eye shield and ortho for maximal eye-sparing. With orbit 
invaded, morbidity follows. Radiotherapy may be the best eye-
preserving option. 
Methods and Materials: Central-axis dose calculation using 
measured % depth dose were compared with central and off-
central axis dose calcs using kVDoseCalc, a dose engine validated 
in kV cone-beam and ortho therapy; and Monte Carlo for e- off-
axis dose calc. We compare conformal RT, arcs, and bump, for 
periocular cancer cases. We compared central axis data for a 4x4 
cm field with: 1) 9 MeV alone; 2) 9 MeV with 0.7 cm custom wax; 
3) 9 MeV, 80% of dose, 100 kV DXR bump, SSD 10 cm, 20% of dose; 
4) 9 MeV, 80% of dose, 200 kV DXR bump, SSD 50 cm, 20% of dose. 
Patients treated at our institution in 10 or 20 treatments 
received 8 or 16 electron treatments (prescribed to account for 
REB of electrons) and 2 or 4 photons treatments, for a total dose 
of 45 Gy in 10 fractions, or 50 Gy in 20 fractions. 
Results: For the case above tables based on measured dose give: 
Surface dose (1) 86%; (2) 90%; (3) 100%; (4) 94% 
Dmax (100%) (1) 2.0 cm; (2) 1.3 cm; (3) 2.0 cm; (4) 2.0 cm  
Dose @ 2.7 cm (1) 89%; (2) 58%; (3) 87%; (4) 91% 
Surface and depth refer to skin surface. Dose is normalized: 
Dmax = 100%. REB and geometry are not included. Comparing 
dynamic conformal ARCs, VMAT, electrons +/- bolus or tantalum 
mesh, and bump show the benefits of 9 MeV with 100-200 kV 
bump. Dose drop off is swift at ~40%/cm beyond D90%. Dose 
spares eye. Low SSD, low kV bump results in best homogeneity 
and surface dose; high kV bump gives best dose at depth. 
Patients can be scanned with a 3D printer wax replica eye shield 
to reduce artifact and enable accurate dose calculation. Actual 
patient results are illustrated with isodose distributions; for 
three clinical cases, the dose above 80% to retina was 2.5 cc for 
conformal treatment, 1.0 cc for dynamic conformal arc and < 0.5 
cc for bumps, demonstrating excellent shielding for the bump 
technique. 
Conclusions: Energy modulation with ortho and electrons can 
result in improved dose distribution. Benefits include: increased 
treatment depth, improved dose homogeneity, no bolus, 
increased shield effectiveness, and reduced penumbra; 
important when treating near the eye. 
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IN VIVO MEASUREMENT OF CEST MRI SIGNAL IN MURINE 
XENOGRAFTS  
Jonathan Klein, Gregory Czarnota, Wilfred Lam, Christine 
Tarapacki, Gregory Stanisz 
University of Toronto, Toronto, ON  
 
Purpose: Chemical exchange saturation transfer magnetic 
resonance imaging (CEST MRI) represents a novel technique for 
detecting cell death in vivo, without the need for injected 
exogenous contrast media or lengthy wait times (as with 
standard anatomical assessment of tumour response). Changes in 
CEST signal parameters corresponding to amide, amine, and 
aliphatic tissues have been suggested to correlate with necrosis. 
In this study, we sought to characterize the changes in CEST 
parameters over time to help determine the optimal time point 
to detect cell death. 
Methods and Materials: CEST MRI data were acquired from 
xenografted MDA-231 breast cancer tumours (n = 12) before and 
after injection with doxorubicin (100 mg/m2) and paclitaxel (50 
mg/m2) chemotherapy. Tumours were scanned at baseline and 
three different treatment times - 4, 8, and 12 hours after 
injection.  
Acquired data was fitted to Lorentzian shapes using a previously 
described method. The peak amplitude is measured as a unitless 
ratio of the measured signal to the CEST signal of bulk water; 
area under the curve is in units of parts per million (ppm), 
related to the resonant frequency of measured protons. Baseline 
CEST parameters were compared to parameters at each 
treatment time using two-tailed T tests with p-value for 
significance of ≤ 0.05. 
Results: For the aliphatic peak, amplitude measured 0.063 ± 
0.009 at baseline, 0.066 ± 0.009 at four hours, 0.095 ± 0.013 at 
8 hours, and 0.065 ± 0.019 at 12 hours post-injection; only the 
change from baseline to eight hours was statistically significant 
(p = 0.02). Significant change in area under the curve (0.051 ± 
0.014 to 0.115 ± 0.015 ppm; p = 0.006) was also observed at eight 
hours post-injection but not at four or 12 hours. For the amine 
peak, significant changes in amplitude were observed at eight 
hours (p < 0.001) and 12 hours (p < 0.001) post-injection; 
amplitude change was not significant at four hours nor was any 
change in peak area at any time point. For the amide peak, no 
significant differences were seen from baseline at any time point 
for peak amplitude or area. 
Conclusions: Our results suggest that eight hours after injection 
of chemotherapy may represent the optimal time to measure cell 
death using CEST MRI, as significant changes were observed in 
aliphatic and amine peak amplitudes at this time point. 
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FLUOROAZOMYCIN ARABINOSIDE (18F-FAZA)  
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Stephen Breen2, Alexander Sun2 
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Purpose: Tumour hypoxia is an adverse prognostic factor in many 
cancers. 18F-FAZA is a hypoxia tracer, which can provide a non-
invasive method of hypoxia imaging with PET, but has not been 
widely studied in NSCLC. This study aims to evaluate the 
feasibility and potential benefits of using 18F-FAZA-PET scans to 
assess NSCLC tumour hypoxia.  
Methods and Materials: Thirteen of the planned 20 patients with 
Stage II – III NSCLC are included thus far in this prospective study 
by imaging with FAZA-PET before initiation of radical chemo- 
radiotherapy. Patients were imaged two hours post-injection 
with FAZA. Attenuation correction was performed using a helical 
computed tomography (hCT) for respiratory gated PET (gPET). 
The exhale bin was used for analysis for the purpose of this study. 
The hypoxic volume (HV) was defined as all voxels within the 
tumour with standard uptake value (SUV) more than three 
standard deviations from the mean values obtained from muscle 
SUV as defined by Mortensen et al. 2012. The Tmax/Mmean ratio 
was defined as maximum tumour SUV divided by the mean 
erector spinae muscle SUV. The hypoxic fraction (HF) was 
determined by dividing the HV by the entire gross tumour volume 
(GTV). Pearson correlation (rho) was performed to evaluate 
whether some of these metrics are correlated.  
Results: A hypoxic volume (HV) in the primary tumour was 
identified in 12 patients (92.3%). The hypoxic fraction (HF) 
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varied from 0 to 46.8% (median 4.2%) in the primary tumour. The 
Tmax/Mmean ranged from 1.37 to 4.23 (median 1.98). There was 
no correlation between lesion size and SUVmax or between lesion 
size and HF, which suggests that larger tumours are not 
necessarily more hypoxic than smaller tumours. A significant 
correlation between Tmax/Mmean and HF was observed (rho = 
0.83, p < 0.001), and between SUVmax and HF (rho = 0.74, p = 
0.004). This may suggest that tumours with a higher SUVmax (ie. 
higher intensity of hypoxia) also have a larger proportional 
volume of hypoxia.  
Conclusions: 18F-FAZA PET scans provide a feasible non-invasive 
method to assess NSCLC tumour hypoxia. A hypoxic volume, as 
detected by 18F-FAZA PET, was present in the majority of NSCLC 
patients in our study. Ongoing trial accrual and follow up of our 
patient cohort will provide more information with regards to the 
imaging and clinical value of 18F-FAZA PET, and we hope to 
correlate these imaging metrics with clinical outcomes. 
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Purpose: Radiotherapy (RT) practice variability in the palliative 
setting is well-documented. Clinical practice guidelines inform 
standardized, evidence-based, beneficial practice, while 
simultaneously discouraging unnecessary or potentially harmful 
practices. The process of creating provincial palliative RT clinical 
practice guidelines is associated with multiple challenges. We 
describe the unique approach required in aligning 
multidisciplinary goals as compared to traditional tumour site-
specific guidelines. 
Methods and Materials: Radiation oncologists from the 
provincial Palliative Care Tumour Team, along with guideline 
specialists from the Guideline Resource Unit, formed the primary 
guideline working group tasked with updating the Palliative RT 
guidelines. Tumour site specific representatives (ex. Central 
Nervous System Tumour Team) were incorporated as needed, as 
well as experts in supportive care, on a guideline by guideline 
basis. For each guideline, a systematic literature review was 
conducted to identify relevant evidence. Recommendations 
were initially developed within the primary working group, then 
revised in collaboration with experts from other disciplines. 
Once working group consensus was reached, guideline 
recommendations were circulated to all radiation oncologists 
and Palliative Tumour Team members for input. After several 
rounds of feedback and modifications, provincial consensus was 
reached. 
Results: Initially, one RT guideline had been created for all 
provincial palliative RT recommendations. These guidelines have 
since been split into smaller, more functional palliative RT 
guidelines: 1) Brain Metastases; 2) Bone Metastases and Spinal 
Cord Compression; 3) Bleeding and Gastrointestinal Obstruction; 
and 4) Superior Vena Cava Obstruction, Dyspnea, and 
Hemoptysis. The majority of recommendations were either 
modified or new due to advancements in research or changes in 
consensus based approaches. In total, 70 recommendations were 
approved. Recommendations were supported by a range of 
evidence from high (level one evidence) to low quality 
(consensus opinion). 
Conclusions: By combining the newly updated palliative RT 
guidelines with an educational intervention, variations in 
practice may be mitigated. Using our model, similar efforts can 
be undertaken in other jurisdictions. 
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SYSTEMATIC REVIEW OF PATIENT REPORTED QUALITY OF LIFE 
FOLLOWING STEREOTACTIC ABLATIVE BODY RADIOTHERAPY FOR 
PRIMARY AND METASTATIC LIVER CANCER 
Adam Mutsaers, Jeffrey Greenspoon, Cindy Walker-Dilks, Anand 
Swaminath 
McMaster University, Hamilton, ON 
 
Purpose: Stereotactic ablative body radiotherapy (SABR) is an 
emerging modality in patients with liver cancer who are 
ineligible for other local therapies. It has been shown to be 
effective with respect to long-term tumour control with minimal 
toxicity. However SABR for liver cancer is not current standard 
of practice despite its potential promise. In order to validate 
increased offering of this promising therapy, objective 
systematic data regarding impact on quality of life (QOL) is 
required. No systematic reviews to date have been performed to 
analyze QOL for primary or metastatic liver cancers. QOL metrics 
are a critical part of therapy evaluation, particularly in disease 
states with short life expectancy. The purpose of this study was 
to conduct a systematic review of evidence surrounding QOL for 
liver SABR.  
Methods and Materials: MEDLINE and EMBASE databases from 
1996 to October 2015 were queried to obtain English language 
studies analysing QOL following SABR for liver cancers. Included 
studies involved patient-reported QOL as either a primary or 
secondary endpoint, along with analysis of QOL change over 
time. Studies were screened by three reviewers, while relevant 
data were abstracted and analyzed by a single reviewer.  
Results: Of 2181 initially screened studies, five met all inclusion 
criteria and were analyzed. Extracted study dates ranged from 
2008 to 2015, included a total of 388 eligible patients, and 4/5 
studies were prospective in design. All were published studies, 
with the exception of one conference abstract. Studies included 
patients with hepatocellular carcinoma, liver metastases and 
intrahepatic cholangiocarcinoma. Extracted studies were 
heterogeneous in dose prescription used (11-70 Gy in 3 – 30 
fractions), as well as in QOL metrics (EORTC QLQ C-15 PAL,/C-
30/LM-21, Euroqol 5D, FACT-Hep, FLIC) and final endpoints 
(range: six weeks to 12 months). Despite this there were few 
clinically or statistically significant declines in QOL scores 
following SABR. Four studies demonstrated increased fatigue 
transiently in the first 1-4 weeks, while two studies showed 
transient worsening of appetite at one month; both metrics 
returned to insignificant difference from baseline by the final 
endpoints. All studies showed no significant decline in QOL at 
their respective endpoints. In studies with overlapping QOL 
tools, estimates of three-month post-SABR global QOL were 
similar. 
Conclusions: Results of this systematic review demonstrate well-
preserved post SABR QOL in patients with otherwise untreatable 
liver cancer, despite heterogeneity amongst the individual 
studies themselves. These findings merit further research to 
increase data collection, to validate QOL tools specific to SABR 
for liver cancers, and to support comparative effectiveness trials 
of SABR with other local modalities in liver cancer including 
surgery, chemoembolization and radiofrequency ablation, with a 
focus on QOL outcomes as an important endpoint. 
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